Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation

Early Phase 1

• Conditions: Glaucoma, Open-Angle
• Interventions: Drug: Netarsudil Ophthalmic

• Registration Number: NCT04234932
• Lead Sponsor: University of the Incarnate Word

Brief Summary

Investigate changes in optical coherence tomography angiography of the optic nerve and macula following topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-06
• Study First Submitted: 2020-01-15
• Study First Submitted QC: 2020-01-15
• Study First Posted: 2020-01-21
• Status Verified: 2020-04
• Last Update Submitted: 2020-04-12
• Last Update Posted: 2020-04-14
• Primary Completion: 2021-01
• Study Completion: 2021-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Normal ocular health

Exclusion Criteria

• Females who are or may be pregnant or who are nursing
• Uncontrolled hypertension
• Allergy to netarsudil or latanoprost

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Netarsudil alone	Netarsudil Ophthalmic	Topical application of netarsudil 0.02%
Netarsudil plus latanoprost	Netarsudil Ophthalmic	Topical application of netarsudil 0.02% with latanoprost 0.005%

Primary Outcome Measures

Name	Time	Method
Peripapillary capillary perfusion density	90 minutes	Mean change in peripapillary capillary perfusion as assessed using optical coherence tomography angiography

Secondary Outcome Measures

Name	Time	Method
Macular capillary perfusion density	90 minutes	Mean change in macular capillary perfusion as assessed using optical coherence tomography angiography

Trial Locations

Locations (1)

University of the Incarnate Word; 🇺🇸 San Antonio, Texas, United States